SANTA CLARA, Calif. — HeartBeam, Inc. (NASDAQ: BEAT) has received the Innovation Award in Remote Cardiac Diagnostics at the 2025 Medical Device Network Excellence Awards, the company announced Tuesday. The award recognizes HeartBeam’s groundbreaking, FDA-cleared electrocardiogram (ECG) technology, which enables clinical-grade cardiac diagnostics outside traditional medical settings.
The Medical Device Network Excellence Awards, backed by GlobalData’s business intelligence, is a highly regarded recognition program in the healthcare industry, evaluating more than a billion data points annually to identify companies making transformative contributions to medical technology.
HeartBeam’s proprietary technology utilizes a unique 3D ECG approach that captures the heart’s electrical activity from three distinct, non-coplanar directions. This data is synthesized into a 12-lead ECG—similar in diagnostic quality to the standard hospital-based ECG—delivered through a compact, credit card-sized, wireless device. This innovation allows patients to record ECG readings at the moment they experience arrhythmia symptoms, dramatically improving access to timely and actionable cardiac care.
“This recognition affirms our vision of transforming how cardiac conditions are monitored and detected and validates our belief that access to high-fidelity ECG data should not be limited by healthcare settings,” said Robert Eno, Chief Executive Officer of HeartBeam. “As we continue to prepare for the market introduction of the HeartBeam System, this award highlights our leadership position in delivering clinically validated, patient-centric solutions to advance remote cardiac care.”
While the 3D ECG device has received FDA clearance, HeartBeam’s 12-lead ECG synthesis software is still under FDA review. Once approved, the company plans to move forward with commercialization, aiming to redefine how arrhythmias and other cardiac conditions are diagnosed and managed remotely.
